DiaSorin started 2022 on a strong note, with both sales and EBITDA exceeding street expectations. While non-COVID-19 offerings continued to gain momentum, the decline in COVID-19 testing sales was also slower than expected, resulting in a 2022 guidance upgrade. While the integration of Luminex is margin dilutive in the near term, the long-term market dynamics remain promising / less prone to (major) performance downgrades vs. supply-chain issues-inflicted MedTechs. Hence, our positive stock reco ....
10 May 2022
Strong Q1 prompts guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q1 prompts guidance upgrade
- Published:
10 May 2022 -
Author:
Anas PATEL -
Pages:
3
DiaSorin started 2022 on a strong note, with both sales and EBITDA exceeding street expectations. While non-COVID-19 offerings continued to gain momentum, the decline in COVID-19 testing sales was also slower than expected, resulting in a 2022 guidance upgrade. While the integration of Luminex is margin dilutive in the near term, the long-term market dynamics remain promising / less prone to (major) performance downgrades vs. supply-chain issues-inflicted MedTechs. Hence, our positive stock reco ....